Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured levels of G-protein-coupled estrogen receptor (GPER1) in HCC and nontumor liver tissues from 68 patients by immunohistochemistry.
|
30641053 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidence suggests that 17β-estradiol (E2) and estrogen receptor (ER) signaling are protective against hepatocellular carcinoma (HCC).
|
30940293 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The presence of plasma SHBG in HCC bearing mice suppressed the levels of steatosis and inflammation in a process mediated by estrogens and estrogen receptor alpha.
|
31168625 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The susceptible FOXA1-Ala83 impairs its interaction with ERα, attenuates transactivation toward some of their dual target genes, such as DIO1, UGT2B17 and NTCP, but correlates with strengthened cellular expression of AFP and elevated AFP serum concentration in HCC patients (n = 1096).
|
31400761 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that few HCC cases expressed ER (5.6%) and PR (4.5%).
|
29563759 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In HCV-associated cirrhosis and HCC the decreased expression of estrogen receptor alfa (ERα) in male patients may explain the worse outcome of HCV infection in men than in women.
|
30349537 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The physiological regulation of Oestrogen receptor α (ERα) and peroxisome proliferator-activated receptor alpha (PPARα) in Hepatocellular carcinoma (HCC) remains unknown.
|
29134746 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The current editorial review critically analyses the study by Iyer et al (<i>WJG</i>, 2017) that investigated the expression of ER subtypes in liver samples collected from patients with a healthy liver, hepatitis C virus cirrhosis, and HCC.
|
29358876 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To begin to understand the potential mechanisms of estrogens' inhibitory effects on HCC development, RNA sequencing was used to generate comprehensive global transcriptome profiles of the human HCC-derived HepG2 cell line following treatment of vehicle (control), estradiol (E2), estrogen receptor alpha- (ER<i>α</i>-) specific agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), or ER<i>β</i>-specific agonist 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) using a small set of cells.
|
30510575 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The roles of DEMs like hsa-mir-221 in HCC through interactions with DEGs such as ESR1 and CXCL12 may provide new clues for the diagnosis and treatment of HCC patients.
|
28302149 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our study identified two genetic variants at 6q25.1 newly associated with HCC risk, suggesting ESR1 and estrogen signaling may play a role in mediating susceptibility to HCC in Chinese population.
|
28334234 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We observed significantly higher mRNA expression of ERα in HCV-related HCC liver tissues as compared to normals (<i>P</i> < 0.05) and ERβ in livers of HCV-related cirrhosis and HCV-related HCC subjects (<i>P</i> < 0.05).
|
29085224 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma.
|
28192186 |
2017 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our hypothesis is based on the fact that liver tissue express ER and its different variants exert multiple functions in various stages of liver disease and participate in an extremely complicated signal transduction process, therefore we believe that the presence of one or more SNPs of ESR1 and ESR2 genes may be related with the increase of risk in developing and the severity of HCC, as well as in the response to different treatments.
|
26804600 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aberrant sera DNA methylation of CDH1, DNMT3b and ESR1 gene promoters could be a biomarker in the early diagnosis of HBV-related HCC.
|
26660680 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma.
|
27899088 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our previous study identified that estrogen receptor alpha (ERα) protein is downregulated in 60% of female HCC cases, via a miR-18a elevation mediated suppression of ERα translation.
|
24975878 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERα overexpression suppressed the proliferation and invasion of hepatocellular carcinoma cells (HCC).
|
26503703 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis indicated that estrogen receptor-α (ERα) was downregulated in HCC tissues and cell lines.
|
25483016 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells.
|
24481452 |
2014 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the CC genotype of PvuII in ESR1 is associated with an increased risk of CHB, HBV-related LC and HCC in Guangxi Zhuang populations.
|
25014269 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the effect of anti-estrogen treatment (fulvestrant) on the biological activity of hepatocellular carcinoma (HCC), involving the estrogen receptor α (ERα) and Wnt pathways, and to evaluate whether ERα and Wnt inhibitory factor-1 (WIF1) could be biomarkers for anti-estrogen clinical therapy.
|
25270093 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current.
|
23042559 |
2013 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in estrogen receptor alpha (ESR1) are reported to be associated with the susceptibility to persistent HBV infection, HBV liver cirrhosis and HBV-related hepatocellular carcinoma (HCC).
|
23109139 |
2013 |